GRTXDGalera Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Galera Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRTXD본 종목 | — | — | — | — | — | 886.2%#3 | — | 20473.8%#1 | — | — | — | — |
| GLMD | $4M#7 | 0.2x#1 | 0.2x#1 | — | — | -37.1%#6 | — | -65.3%#6 | — | — | -62.3%#7 | — |
| GRCE | $34M#6 | — | 0.5x#2 | 0.3x#1 | — | 18.6%#4 | -11.1%#3 | -12.2%#5 | — | — | -27.5%#5 | — |
| GSK | $222.3B#1 | — | — | — | — | — | — | — | — | — | 37.2%#2 | — |
| HCM | $10.1B#2 | 22.2x#2 | 8.1x#3 | 18.4x#2 | -13.0%#1 | 1111.0%#1 | -7.1%#1 | 36.9%#2 | 0.0%#1 | — | -32.6%#6 | — |
| HELP | $174M#3 | — | — | — | — | — | — | — | — | — | 6.7%#3 | — |
| HMDCF | — | — | — | — | -13.0%#1 | 1111.0%#1 | -7.1%#1 | 36.9%#2 | 0.0%#1 | — | — | — |
| HSTC | — | — | — | — | — | -0.8%#5 | — | -11.8%#4 | — | — | — | — |
| HYFT | $63M#5 | — | — | — | — | — | — | — | — | — | -17.2%#4 | — |
| IFRX | $127M#4 | — | — | — | — | — | — | — | — | — | 102.3%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-08-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice